What We Believe

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

It is not a matter of editorial opinion to say these words: Black Lives Matter.

The existence of systemic racism, social inequality, and health disparities is indisputable, and not a matter of bias or opinion. This is grounded in science and data.

Cancer does not discriminate. Our social infrastructure does.

The Cancer Letter strives to give you unbiased, balanced coverage grounded in standards of evidence-based medicine, the principles of peer review, disclosures, health equity, and social justice.

Our coverage since 1973 has adhered to this mission. But all of us must do more.

Diversity is fundamental to fair and balanced coverage, and to achieving health equity. As a news publication, we must amplify the voices of those who have been historically marginalized. This requires an ongoing, concerted effort in a world where the people who hold the keys to power are disproportionately white and male.

NCI should be commended for emphasizing Community Outreach and Engagement as a key criterion for the designation of cancer centers. However, as a logical next step, we must also examine diversity at the cancer centers.

Of the 71 directors of NCI-Designated Cancer Centers, the vast majority are white and male. One is African American. Nine are women.

What does the leadership pipeline look like? We don’t know. No robust data exist on the diversity among directors and deputy directors of NCI-designated cancer centers. These data should be generated, and made publicly available.

All of us—scientists, physicians, and journalists—have a role to play in bringing forward diverse viewpoints. It’s fair, it’s equitable, and it’s essential to good science.

“In my experience, our endemic institutional racism is, and has always been, a public health issue,” Robert Winn writes. “In fact—as a result of the COVID-19 disaster—we are all now finally recognizing that racism is a contributing factor to chronic diseases, including cancer.”

Alexandria Carolan
Alexandria Carolan
Reporter
Katie Goldberg
Director of Operations
Matthew Bin Han Ong
Matthew Bin Han Ong
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
Alexandria Carolan
Alexandria Carolan
Reporter
Katie Goldberg
Director of Operations
Matthew Bin Han Ong
Matthew Bin Han Ong
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login